Connect with us

Technology

NEO Battery to Strategically Increase Ownership of Korean Operating Subsidiary

Published

on

TORONTO, June 29, 2026 /CNW/ – NEO Battery Materials Ltd. (“NEO” or the “Company”) (TSXV: NBM) (OTC: NBMFF), a low-cost, silicon-enhanced battery manufacturer enabling high-performance capabilities for drones, robotics, and physical AI, is pleased to strategically acquire an additional 10% interest in its operating subsidiary, NEO Battery Korea Co., Ltd. (“NBM Korea”), through a Stock Purchase Agreement dated June 26, 2026, from Automobile & PCB Inc. (“A&P”), strengthening NEO’s ownership of a key operating asset.

Since expanding operations through the Gimje battery manufacturing facility, NBM Korea has initiated and continues to service Fortune 500 automotive and international drone and battery value chain companies, with foundry products and high-performance solutions targeted for defense and government customers. The increased ownership underscores NBM Korea’s growing strategic and operational importance to the Company’s interests and scale-up.

NEO has acquired 120,786 common shares of NBM Korea for an aggregate purchase price of KRW 715,542,466 (or approximately CAD 662,539) (the “Transaction”). Upon closing, NEO will directly own 1,156,102 common shares of NBM Korea, representing approximately 90% of the issued and outstanding common shares. The Transaction remains subject to customary closing conditions, including the acceptance by the TSX Venture Exchange (“TSXV”).

As NBM Korea progresses toward scaled battery manufacturing with its first and expansion factories, acquiring a greater interest at this stage, ahead of full production ramp, positions the Company and its stakeholders to capture a greater share of the value and economics created as both facilities mature. Furthermore, defense and government customers have increased scrutiny of suppliers’ ownership and control during qualification and procurement reviews. Management considers consolidating ownership will reduce due diligence complexity and strengthen the Company as a controlled, traceable supplier, enabling it to compete for additional contract awards. Simplified capital structure will further allow greater flexibility in structuring future financings at the subsidiary level, including potential participation by strategic partners and government-linked investors.

Pursuant to TSXV Policy 1.1, A&P is considered a Non-Arm’s Length Party with a board member in NBM Korea and held 258,828 common shares of NBM Korea prior to the Transaction. The Transaction is not subject to disinterested shareholder approval, and there are no shares, warrants, or securities of the Company issued as finder’s fees.

About NEO Battery Materials Ltd.

NEO Battery Materials is a Canadian-South Korean battery technology company focused on developing and producing silicon-enhanced lithium-ion batteries in drones, robotics, physical AI, electric vehicles, and energy storage systems. With a patent-protected, low-cost silicon manufacturing process, NEO Battery enables longer-running and ultra-fast charging properties and provides end-to-end battery solutions from materials selection, cell architecture, and process optimization. The Company aims to be a globally-leading producer of high-performance lithium-ion batteries and materials, building a secure, robust battery supply chain for Western manufacturers. For more information, please visit the Company’s website at: https://www.neobatterymaterials.com/.

On Behalf of the Board of Directors
Spencer Huh
Director, President, and CEO

This news release includes certain forward-looking statements as well as management’s objectives, strategies, beliefs and intentions. All information contained herein that is not clearly historical in nature may constitute forward-looking information. Generally, such forward-looking information can be identified notably by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information, including but not limited to: volatile stock prices; the general global markets and economic conditions; the possibility of write-downs and impairments; the risk associated with the research and development of battery-related technologies; the risk associated with the effectiveness and feasibility of battery material, electrode, and cell technologies that have not yet been tested or proven on commercial scale or under real-world operating conditions; the risks associated with battery-related manufacturing process scale-up, including maintaining consistent material, component, and cell quality, production yields, and process reproducibility at a pilot, semi-commercial, or commercial scale; the risks associated with compatibility of existing battery chemistries, formulations, components, or designs; unforeseen risks associated with entering into and maintaining collaborations, joint ventures, partnerships, or commercial contracts with battery cell manufacturers, original equipment manufacturers, and various companies in the global battery and downstream end-user supply chain; the risks associated with the failure to develop and produce commercially viable battery-related products or that technical goals may not be achieved within expected timelines or budgets under a joint development or collaboration; the risks associated with the Company’s technologies and products not meeting performance requirements or customer specifications; the risks that prototype and pilot-scale products do not advance into commercially produced products or translate into commercial orders; the risk associated with battery components and cell purchase orders and offtake supply that may not be fulfilled in full, on time, or at all as actual revenue realization depends on delivery schedules, achievement of technical milestones, and customer acceptance and validation; the risk associated with losing official vendor registration or status with existing customers; counterparty risk upon delivery of prototype and commercial products; the risks associated with constructing, completing, securing, and financing pilot, semi-commercial, and commercial battery materials, components, and cell manufacturing facilities including the Canadian and South Korean facilities; the risks associated with potential delays or increased costs with site preparation, equipment procurement and installation, and facility commissioning; the risks associated with integrating silicon anode material production, electrode manufacturing, and cell assembly within a single operational cluster or the Company’s business portfolio; the risks associated with supply chain disruptions or cost fluctuations in raw materials, processing chemicals, and additive prices, impacting production costs and commercial viability; the risks associated with uninsurable risks arising during the course of research, development and production; competition faced by the Company in securing experienced personnel, contracts and sales, and financing; access to adequate infrastructure and resources to support battery materials, components, and cell research and development activities; the risks associated with changes in the technology regulatory regime governing the Company; the risks associated with the timely execution of the Company’s strategies and business plans; the risks associated with the lithium-ion battery industry and end-users’ demand and adoption of the Company’s silicon anode technology and battery products; market adoption and integration challenges, including the difficulty of incorporating silicon anodes and silicon battery products within battery manufacturers and OEMs’ systems; the risks associated with the various environmental and political regulations the Company is subject to; risks related to regulatory and permitting delays; the reliance on key personnel; liquidity risks; the risk of litigation; risk management; and other risk factors as identified in the Company’s recent Financial Statements and MD&A and in recent securities filings for the Company which are available on www.sedarplus.ca. Forward-looking information is based on assumptions management believes to be reasonable at the time such statements are made, including but not limited to, continued R&D and commercialization activities, no material adverse change in precursor, raw material, equipment, and relevant cost prices, development and commercialization plans to proceed in accordance with plans and such plans to achieve their stated expected outcomes, receipt of required regulatory approvals, and such other assumptions and factors as set out herein. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in the forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such forward-looking information. Such forward-looking information has been provided for the purpose of assisting investors in understanding the Company’s business, operations, research and development, and commercialization plans and may not be appropriate for other purposes. Accordingly, readers should not place undue reliance on forward-looking information. Forward-looking information is made as of the date of this presentation, and the Company does not undertake to update such forward-looking information except in accordance with applicable securities laws.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE NEO Battery Materials Ltd.

Continue Reading

Technology

Signant Health and Lothar Medical Sign Letter of Intent to Commercialize ALDS PRO for Clinical Trials

Published

on

By

Collaboration creates a path to combine Signant’s market-leading eCOA and digital endpoint capabilities with Lothar Medical’s three-in-one ALDS PRO respiratory assessment system

PHILADELPHIA, and WÜRZBURG, Germany, Sept. 5, 2026 /PRNewswire/ — Signant Health, a leading provider of evidence generation solutions for clinical trials, and Lothar Medical today announced that they have signed a letter of intent outlining a planned strategic collaboration to bring Lothar Medical’s next-generation pulmonary function technology to the global clinical trial market.

The companies are discussing plans to develop an integrated clinical trial offering that combines Signant’s electronic clinical outcome assessment (eCOA) solutions, including TrialMax®, with Lothar Medical’s ALDS PRO, an all-in-one respiratory assessment system. The planned offering would help sponsors connect patient-reported symptoms and daily functioning with objective measures of pulmonary function and airway inflammation, providing a more complete view of treatment effects in respiratory studies.

ALDS PRO combines three essential respiratory assessments — spirometry, airway oscillometry, and fractional exhaled nitric oxide (FeNO) –in one portable, guided system. By replacing multiple devices and disconnected assessment workflows with a single solution, the combined technologies will simplify equipment management and training for sites, promote more consistent data collection across study locations, and create a more straightforward assessment experience for patients.

Oscillometry is increasingly used alongside spirometry and FeNO in clinical trials to capture airway mechanics during normal tidal breathing. FeNO provides an objective measure associated with airway inflammation. Bringing these complementary assessments together will help sites collect broader respiratory evidence with less workflow fragmentation and operational challenges.

As part of the planned commercialization framework, the companies intend Signant to serve as the exclusive provider of ALDS PRO for drug trial applications. Signant and Lothar Medical will work together on the scientific, technical, operational, and commercial activities required to prepare the solution for use by study sponsors and clinical research sites.

The collaboration supports Signant’s Sensor-Enhanced eCOA (SEE) strategy, which brings together patient-reported outcomes and sensor-generated evidence through a unified scientific, operational, and technology approach. Signant’s acquisition of Ametris, formerly ActiGraph, combined its eCOA capabilities with validated wearable-derived digital outcome measures, creating a platform designed to connect what patients report with continuous, objective measures of how they move, sleep, and function.

“Respiratory development programs increasingly need evidence that reflects both the patient’s real life experience and the underlying physiology of disease,” said Roger Smith, chief executive officer of Signant Health. “Our planned collaboration with Lothar Medical creates a compelling path to bring its innovative pulmonary function technology to clinical research. By combining ALDS PRO with TrialMax and Ametris, we intend to give sponsors an integrated and more accurate way to capture patient-reported, respiratory, and movement-based evidence while designing an experience that is more manageable for sites and patients.”

“ALDS PRO was created to make comprehensive pulmonary assessment more accessible and less fragmented,” said David Markus Thomas, managing director of Lothar Medical. “Signant brings the eCOA leadership, digital endpoint expertise, scientific depth, and global clinical trial infrastructure needed to translate that vision into a purpose-built solution for research. This planned collaboration represents an important step toward making ALDS PRO available to sponsors and sites conducting respiratory trials around the world.”

Experience ALDS PRO at ERS 2026

The companies are announcing the planned collaboration ahead of the European Respiratory Society International Congress 2026, taking place September 5–9 in Barcelona, Spain. The two companies will staff a booth at the Congress to promote the planned partnership and gain feedback from sponsors.

Congress attendees are invited to visit Lothar Medical at booth U.02B to see demonstrations of:

Lothar Medical ALDS PRO, which combines forced spirometry, airway oscillometry, and FeNO in one portable system.
Ametris ActiGraph LEAP®, a medical-grade multisensor watch that supports the collection of movement-based digital endpoints and continuous measures of activity, sleep, and mobility.

The demonstrations will illustrate the companies’ shared vision for connecting pulmonary assessments, patient-reported outcomes, and movement-based digital measures to build a more comprehensive picture of patient health in respiratory clinical trials. Demonstrations are for showcasing device functionality and do not indicate current commercial availability of an integrated Signant–Lothar solution.

To learn more about Signant’s Sensor-Enhanced eCOA strategy, visit discover.signanthealth.com/sensor-enhanced-ecoa.

About Signant Health

Signant Health is the evidence generation company, leveraging software, deep therapeutic and scientific knowledge, and operational expertise to deliver quality evidence across traditional, virtual, and hybrid trial models. For over 25 years, 600+ sponsors and CROs of all sizes – including all Top 20 pharma – have trusted Signant’s comprehensive eClinical solutions. Our clinical outcome assessments (eCOA, clinician ratings, cognitive testing) and wearable digital health technologies powered by Ametris provide the industry’s most comprehensive evidence generation capabilities, alongside EDC, eConsent, RTSM, supply chain management, and data quality analytics. Learn more at www.signanthealth.com.

About Lothar Medical

Lothar Medical develops respiratory diagnostic technologies designed to make lung assessment faster, more comprehensive, and easier to perform. Its portable ALDS platform combines respiratory measurements with cloud-based analysis to support efficient, multidimensional lung-function assessment. ALDS PRO integrates airway oscillometry, forced spirometry, and FeNO measurement in a single system. Learn more at lothar-medical.com.

View original content:https://www.prnewswire.com/news-releases/signant-health-and-lothar-medical-sign-letter-of-intent-to-commercialize-alds-pro-for-clinical-trials-302870655.html

SOURCE Signant Health

Continue Reading

Technology

Creality Unveils K3, SPARKX i8 and Expanded Creative Ecosystem at IFA 2026

Published

on

By

BERLIN, Sept. 5, 2026 /PRNewswire/ — Creality, a global leader in 3D printing, unveiled its latest product portfolio at IFA 2026, bringing together new developments across multi-channel and multi-material 3D printing, filament recycling, resin printing, 3D scanning, laser creation, and digitally manufactured consumer products.

The new lineup arrives with recognition from the IFA Innovation Awards 2026, with the Creality M1 Filament Maker named a Winner and the new flagship K3 recognised as an Honoree. The honours highlight Creality’s continued innovation across both next-generation 3D printing and more sustainable material workflows.

Leading Creality’s 3D printing lineup are the new K3 and SPARKX i8, representing two approaches to more efficient and versatile multicolour printing. They are joined by the large-format Ender-3 V3 Mega, the new HALOT-X1 Max and HALOT-X1 Neo resin printers, the portable Pika 3D scanner, Creality’s latest A1C and T1C laser systems, and Nexbie 3D-printed footwear.

K3: Award-Recognised Multi-Channel and Multi-Material Innovation

Recognised as an IFA Innovation Awards 2026 Honoree, the K3 represents the latest evolution of Creality’s flagship K Series. Powered by the built-in KliTek™ multi-channel system, it enables nozzle swaps in just 4.8 seconds, eliminating the repeated filament retraction, reloading, and heavy purging typical of single-nozzle multicolour printers. The system cuts total print time by up to 80%* and material waste by up to 85%*.

With optional add-on accessories, the K3 unlocks advanced multi-material capabilities and mixed-nozzle printing. It handles soft, flexible filaments including TPU 85A–95A, combines materials of varying hardness in a single build, and supports hybrid nozzle configurations—pairing a 0.4 mm nozzle for high-precision outer walls with a 0.8 mm nozzle for rapid infill, boosting print efficiency by up to 30%*. Combined with an AI-assisted workflow and an open ecosystem, the K3 expands creative possibilities for makers, print farm operators, and industrial professionals alike.

*Data based on Creality’s internal testing. Actual results may vary depending on testing conditions.

M1: Award-Winning Filament Recycling

Named a Winner at the IFA Innovation Awards 2026, the M1 Filament Maker extends 3D printing into a more circular material workflow. Working with the R1 Shredder, the system enables users to process plastic and failed prints into new filament, while also supporting customised material formulations for greater experimentation and reuse.

SPARKX i8: Efficient Four-Colour Creation

The SPARKX i8 makes four-colour printing faster, cleaner, and easier to use. Its four-channel toolhead and 4-in-1 hotend keep four filaments ready at once, while a short shared melt zone minimises purging between colours, reducing material waste and transition time.

Combined with AI-assisted creation and intelligent printing features, the i8 is designed to shorten the journey from an initial idea to a finished multicolour object with fewer manual steps.

Expanding the AI-Powered Creative Ecosystem

Creality has also expanded its FDM lineup with the Ender-3 V3 Mega, combining a 420 × 420 × 420 mm build volume with support for 85A–95A TPU. Designed for large models and batch production, it brings greater scale and material flexibility to the Ender platform.

The resin lineup has grown with HALOT-X1 Max and HALOT-X1 Neo. The X1 Neo offers a compact, accessible entry point with high-resolution printing and AI-assisted creation, while the flagship X1 Max combines a 17.1 L build volume, 16K display, 40°C active heating, quad-lead-screw architecture, and a 5 L smart resin system for larger, continuous production.

For 3D scanning, the new Pika packs a seven-line blue laser and NIR scanning into a portable 260 g body, delivering accuracy up to 0.03 mm and scanning speeds of up to 110 fps. AI-powered processing and wireless connectivity further simplify the path from physical objects to editable digital models.

Creality’s latest laser solutions further extend the ecosystem into engraving, cutting, marking, and personalisation, giving creators more ways to turn digital designs into physical objects.

Beyond creative tools, Creality is showcasing the possibilities of digital manufacturing through Nexbie and its latest 3D-printed footwear collection. Models including CloudWing, CloudSpark, and CloudX combine DLP printing, advanced elastomers, and digitally engineered structures to explore new approaches to footwear design and production.

As IFA continues, Creality’s booth H20.143 remains open to visitors looking to explore its latest products and hands-on experiences. From the award-recognised K3 and M1 to new developments across multicolour printing, scanning, laser processing and digitally manufactured consumer products, the portfolio reflects Creality’s broader ambition to make advanced digital fabrication more accessible across the creative workflow.

View original content to download multimedia:https://www.prnewswire.com/news-releases/creality-unveils-k3-sparkx-i8-and-expanded-creative-ecosystem-at-ifa-2026-302870657.html

SOURCE Creality

Continue Reading

Technology

TCL Inspires Her Greatness at the FIBA Women’s Basketball World Cup 2026

Published

on

By

As a FIBA Global Partner, TCL brings TCLforHer to life through technology-enabled fan experiences that celebrate women athletes, connect fans, and extend the energy of the game beyond the court.

BERLIN, Sept. 5, 2026 /PRNewswire/ — The FIBA Women’s Basketball World Cup 2026 takes place in Berlin this September, with the world’s top women’s basketball teams competing on the sport’s biggest stage. As a FIBA Global Partner, TCL is bringing its TCLforHer initiative to life at the tournament with a series of technology-enabled fan experiences that let standout performances by women athletes be seen, shared and celebrated by audiences worldwide.

With the FIBA Women’s Basketball World Cup 2026 taking place in Berlin alongside IFA 2026, TCL is using this rare meeting of global sport and consumer technology to connect the energy of the court with the future of smart living.

“The FIBA Women’s Basketball World Cup is a powerful platform for celebrating the confidence, resilience and teamwork that define women’s basketball,” said Wei Xue, Vice President and ESG Director of TCL Technology and Chairman of the TCL Charity Foundation. “Through TCLforHer and our partnership with FIBA, TCL is using technology not only to enhance the fan experience, but also to help the stories and achievements of women athletes inspire more women around the world.”

TCLforHer Champions Women’s Sport On and Off the Court

During the tournament, the TCL Player of the Game award will honor standout performances across 36 games, recognizing the skill, strength, leadership and resilience shown on the court.

Beyond the court, TCL’s commitment to celebrating women’s achievements extends through TCLforHer, a global initiative launched in 2021 that brings together technology, sport, and education to support women’s personal development. Through FIBA’s “Her World, Her Rules,” TCL encourages girls and women to build confidence, challenge limitations and pursue their potential through sport.

From the Court to the Living Room, TCL Brings Elite Sport Closer to Fans

TCL’s support is visible throughout the tournament through courtside advertising boards, on-court decals, media backdrops and a dedicated fan interactive booth at Berlin Arena, while fan activations—including TCL Lucky Frame, giant TIFO display and TV giveaways—turn live game highlights into memorable fan moments.

Outside the arena, TCL is extending the passion of the game to home entertainment and mobile through TVs, RayNeo glasses, and mobile devices. Whether watching the game on a large living-room screen, exploring more personal viewing through wearable displays, or following and sharing moments on mobile devices, TCL is bringing the game’s energy into more everyday settings through a richer range of on-screen experiences.

Inspiring Greatness Through Global Sports Engagement

Sport is a key pillar of TCL’s global brand strategy and a shared language through which it creates emotional connections with audiences across cultures. Spanning football, basketball, American football, esports, and more, TCL is building a global partnership network that connects fans with world-class sport.

As an Official Worldwide Olympic and Paralympic Partner and FIBA Global Partner, TCL brings international sporting moments into everyday life through its display technologies, smart home appliances, and smart living experiences. Beyond these global sports platforms, TCL is also connecting with fans locally through football partnerships with major European national teams and clubs, creating more everyday touchpoints for fans to experience their favorite sports and teams. Together, these partnerships help TCL bring fans closer to their favorite athletes and teams, igniting more moments that Inspire Greatness every day.

About TCL

Founded in 1981, TCL—short for “The Creative Life”—is dedicated to empowering smarter, healthier lifestyles through next-generation experiences. Operating through two independent entities, TCL Industries and TCL Technology, TCL delivers innovative solutions spanning TVs, smartphones, audio products, smart home devices, display technologies, and clean energy.

Today, with 50 R&D centers and 47 manufacturing bases globally, TCL operates in over 160 countries and regions, reinforcing its position as a globally competitive smart technology brand. To further inspire greatness, TCL has become an official Worldwide Olympic and Paralympic Partner in the Home Audiovisual Equipment and Home Appliances category. 

https://www.tcl.com/global/en
 

View original content to download multimedia:https://www.prnewswire.com/news-releases/tcl-inspires-her-greatness-at-the-fiba-womens-basketball-world-cup-2026-302870648.html

SOURCE TCL Technology Group Corporation

Continue Reading

Trending